The FDA has modified the safety labeling for extended-release (ER) and long-acting (LA) opioid analgesics, as well as required further postmarketing studies to be conducted by the manufacturers of the agents. Although many of the changes reflect requests made in a petition from a physicians’ group looking to limit the prescribing and use of opioids for safety reasons, many of the group’s recommendations were not adopted by the FDA...

Amylin Pharmaceuticals, Inc. (AMLN) and Alkermes plc (ALKS) recently announced the availability of their type II diabetes treatment, Bydureon (exenatide once-weekly) in the US...

The Alliance for Continuing Education in the Health Professions annual conference in January included a session on on risk evaluation and mitigation strategy, or REMS, for long-acting and extended-release opioids...
Bayer HealthCare is working with the Ludwig Boltzmann Institute (LBI) for Lung Vascular Research in the research area of lung vascular diseases - especially pulmonary hypertension...

In The News Archives

 

Next page: Events
 
Register for periodic industry updates:

2017© 2015 ParagonRx. All rights reserved.